|
NZ605079A
(en)
*
|
2010-06-03 |
2015-08-28 |
Alnylam Pharmaceuticals Inc |
Biodegradable lipids for the delivery of active agents
|
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP3431485B2
(en)
|
2010-10-01 |
2024-09-04 |
ModernaTX, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
WO2012135805A2
(en)
|
2011-03-31 |
2012-10-04 |
modeRNA Therapeutics |
Delivery and formulation of engineered nucleic acids
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP2763701B1
(en)
|
2011-10-03 |
2018-12-19 |
Moderna Therapeutics, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
JP6305343B2
(ja)
*
|
2011-12-07 |
2018-04-04 |
アルニラム・ファーマシューティカルズ・インコーポレーテッド |
活性薬剤の送達のための分岐アルキルおよびシクロアルキルを末端とする生分解性脂質
|
|
CA2856742A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
KR20140102759A
(ko)
|
2011-12-16 |
2014-08-22 |
모더나 세라퓨틱스, 인코포레이티드 |
변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
|
|
ES2762873T3
(es)
|
2012-03-29 |
2020-05-26 |
Translate Bio Inc |
Lípidos catiónicos ionizables
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
DE18200782T1
(de)
|
2012-04-02 |
2021-10-21 |
Modernatx, Inc. |
Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
|
|
US9878056B2
(en)
|
2012-04-02 |
2018-01-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
|
AU2013249548A1
(en)
|
2012-04-19 |
2014-11-06 |
Sirna Therapeutics, Inc. |
Novel diester and triester based low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
|
|
CA2892529C
(en)
|
2012-11-26 |
2023-04-25 |
Moderna Therapeutics, Inc. |
Terminally modified rna
|
|
CA2891911C
(en)
|
2012-12-07 |
2023-03-07 |
Alnylam Pharmaceuticals, Inc. |
Improved nucleic acid lipid particle formulations
|
|
WO2014152211A1
(en)
|
2013-03-14 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
DK3019619T3
(da)
*
|
2013-07-11 |
2021-10-11 |
Modernatx Inc |
Sammensætninger, der omfatter syntetiske polynukleotider, som koder for crispr-beslægtede proteiner, og syntetiske sgrna'er, og anvendelsesfremgangsmåder
|
|
EP3041934A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
WO2015048020A2
(en)
*
|
2013-09-24 |
2015-04-02 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for the manufacture of lipid nanoparticles
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
EA201690675A1
(ru)
|
2013-10-03 |
2016-08-31 |
Модерна Терапьютикс, Инк. |
Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
|
|
KR102507624B1
(ko)
|
2013-11-22 |
2023-03-09 |
미나 테라퓨틱스 리미티드 |
Ｃ/ｅｂｐ 알파 짧은 활성화 ｒｎａ 조성물 및 사용 방법
|
|
PT3083556T
(pt)
*
|
2013-12-19 |
2020-03-05 |
Novartis Ag |
Lípidos e composições lipídicas para a entrega de agentes ativos
|
|
WO2015095346A1
(en)
*
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
|
HRP20221536T1
(hr)
|
2014-06-25 |
2023-02-17 |
Acuitas Therapeutics Inc. |
Novi lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina
|
|
WO2016011226A1
(en)
|
2014-07-16 |
2016-01-21 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
WO2016010840A1
(en)
|
2014-07-16 |
2016-01-21 |
Novartis Ag |
Method of encapsulating a nucleic acid in a lipid nanoparticle host
|
|
US9492594B2
(en)
|
2014-07-18 |
2016-11-15 |
M.A. Med Alliance SA |
Coating for intraluminal expandable catheter providing contact transfer of drug micro-reservoirs
|
|
US11406742B2
(en)
|
2014-07-18 |
2022-08-09 |
M.A. Med Alliance SA |
Coating for intraluminal expandable catheter providing contact transfer of drug micro-reservoirs
|
|
US20170210788A1
(en)
|
2014-07-23 |
2017-07-27 |
Modernatx, Inc. |
Modified polynucleotides for the production of intrabodies
|
|
PL3178807T3
(pl)
*
|
2014-08-07 |
2020-08-24 |
Takeda Pharmaceutical Company Limited |
Lipid kationowy
|
|
JP6731912B2
(ja)
|
2014-09-05 |
2020-07-29 |
ノバルティス アーゲー |
活性物質の送達用の脂質および脂質組成物
|
|
WO2016100716A1
(en)
|
2014-12-18 |
2016-06-23 |
Vasant Jadhav |
Reversirtm compounds
|
|
CN107207413B
(zh)
|
2014-12-26 |
2019-04-30 |
卫材R&D管理有限公司 |
阳离子性脂质
|
|
JP6910947B2
(ja)
*
|
2015-03-24 |
2021-07-28 |
協和キリン株式会社 |
核酸含有脂質ナノ粒子
|
|
CA2990202A1
(en)
|
2015-06-29 |
2017-01-05 |
Acuitas Therapeutics Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
DK3350157T3
(da)
|
2015-09-17 |
2022-02-14 |
Modernatx Inc |
Forbindelser og sammensætninger til intracellulær afgivelse af terapeutiske midler
|
|
MA46316A
(fr)
|
2015-10-22 |
2021-03-24 |
Modernatx Inc |
Vaccin contre le cytomégalovirus humain
|
|
WO2018081480A1
(en)
|
2016-10-26 |
2018-05-03 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
PT3368507T
(pt)
|
2015-10-28 |
2023-02-07 |
Acuitas Therapeutics Inc |
Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos
|
|
MD3386484T2
(ro)
|
2015-12-10 |
2022-11-30 |
Modernatx Inc |
Compoziții și metode de livrare a unor agenți terapeutici
|
|
AU2016377681B2
(en)
|
2015-12-22 |
2021-05-13 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
EP4039699A1
(en)
|
2015-12-23 |
2022-08-10 |
ModernaTX, Inc. |
Methods of using ox40 ligand encoding polynucleotides
|
|
US20190022247A1
(en)
*
|
2015-12-30 |
2019-01-24 |
Acuitas Therapeutics, Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
US20190241658A1
(en)
|
2016-01-10 |
2019-08-08 |
Modernatx, Inc. |
Therapeutic mRNAs encoding anti CTLA-4 antibodies
|
|
WO2017201342A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding jagged1 for the treatment of alagille syndrome
|
|
WO2017201332A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding acyl-coa dehydrogenase, very long-chain for the treatment of very long-chain acyl-coa dehydrogenase deficiency
|
|
EP3476832B1
(en)
*
|
2016-06-24 |
2023-04-19 |
Eisai R&D Management Co., Ltd. |
Cationic lipid
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
RU2765874C2
(ru)
|
2016-10-26 |
2022-02-04 |
МОДЕРНАТиЭкс, ИНК. |
Матричные рибонуклеиновые кислоты для усиления иммунных ответов и способы их применения
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
EP3576780A1
(en)
|
2017-02-01 |
2019-12-11 |
Modernatx, Inc. |
Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
|
|
ES2911186T3
(es)
|
2017-03-15 |
2022-05-18 |
Modernatx Inc |
Formas cristalinas de aminolípidos
|
|
AU2018234692B2
(en)
|
2017-03-15 |
2022-06-02 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
CA3055653A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
|
JP7162021B2
(ja)
|
2017-03-17 |
2022-10-27 |
ニューカッスル ユニバーシティ |
筋ジストロフィーを治療するためのマイクロジストロフィン断片のアデノ随伴ウイルスベクター送達
|
|
EP3607074A4
(en)
|
2017-04-05 |
2021-07-07 |
Modernatx, Inc. |
REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
|
|
US11357856B2
(en)
|
2017-04-13 |
2022-06-14 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
WO2018191719A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipid delivery of therapeutic agents to adipose tissue
|
|
US11820728B2
(en)
|
2017-04-28 |
2023-11-21 |
Acuitas Therapeutics, Inc. |
Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
WO2018213731A1
(en)
|
2017-05-18 |
2018-11-22 |
Modernatx, Inc. |
Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
|
|
EP3625345B1
(en)
|
2017-05-18 |
2023-05-24 |
ModernaTX, Inc. |
Modified messenger rna comprising functional rna elements
|
|
EP3638292A1
(en)
|
2017-06-14 |
2020-04-22 |
ModernaTX, Inc. |
Polynucleotides encoding coagulation factor viii
|
|
WO2018232120A1
(en)
|
2017-06-14 |
2018-12-20 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
US11786607B2
(en)
|
2017-06-15 |
2023-10-17 |
Modernatx, Inc. |
RNA formulations
|
|
EP3668833A1
(en)
|
2017-08-16 |
2020-06-24 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
US11542225B2
(en)
|
2017-08-17 |
2023-01-03 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036030A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
|
WO2019036000A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
|
EP3668522B1
(en)
|
2017-08-18 |
2024-09-11 |
ModernaTX, Inc. |
Efficacious mrna vaccines
|
|
MX2020002348A
(es)
|
2017-08-31 |
2020-10-08 |
Modernatx Inc |
Métodos de elaboración de nanopartículas lipídicas.
|
|
EP3679140B1
(en)
|
2017-09-08 |
2022-11-16 |
MiNA Therapeutics Limited |
Stabilized cebpa sarna compositions and methods of use
|
|
AU2018330495A1
(en)
|
2017-09-08 |
2020-03-26 |
Mina Therapeutics Limited |
Stabilized hnf4a sarna compositions and methods of use
|
|
JP6826014B2
(ja)
*
|
2017-09-13 |
2021-02-03 |
株式会社東芝 |
生分解性化合物、脂質粒子、脂質粒子を含む組成物、およびキット
|
|
WO2019089828A1
(en)
|
2017-10-31 |
2019-05-09 |
Acuitas Therapeutics, Inc. |
Lamellar lipid nanoparticles
|
|
WO2019104152A1
(en)
|
2017-11-22 |
2019-05-31 |
Modernatx, Inc. |
Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
|
|
EP3714045A1
(en)
|
2017-11-22 |
2020-09-30 |
Modernatx, Inc. |
Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia
|
|
US11939601B2
(en)
|
2017-11-22 |
2024-03-26 |
Modernatx, Inc. |
Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
|
|
EP3733647B1
(en)
|
2017-12-27 |
2022-06-15 |
Eisai R&D Management Co., Ltd. |
Cationic lipid
|
|
US11802146B2
(en)
|
2018-01-05 |
2023-10-31 |
Modernatx, Inc. |
Polynucleotides encoding anti-chikungunya virus antibodies
|
|
WO2019200171A1
(en)
|
2018-04-11 |
2019-10-17 |
Modernatx, Inc. |
Messenger rna comprising functional rna elements
|
|
US11566246B2
(en)
|
2018-04-12 |
2023-01-31 |
Mina Therapeutics Limited |
SIRT1-saRNA compositions and methods of use
|
|
EP3796893A1
(en)
|
2018-05-23 |
2021-03-31 |
Modernatx, Inc. |
Delivery of dna
|
|
JP7488193B2
(ja)
*
|
2018-05-24 |
2024-05-21 |
トランスレイト バイオ， インコーポレイテッド |
チオエステルカチオン性脂質
|
|
MY208145A
(en)
|
2018-06-18 |
2025-04-18 |
Res Inst Nationwide Childrens Hospital |
Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
|
|
US11827877B2
(en)
|
2018-06-28 |
2023-11-28 |
Crispr Therapeutics Ag |
Compositions and methods for genomic editing by insertion of donor polynucleotides
|
|
US20220184185A1
(en)
|
2018-07-25 |
2022-06-16 |
Modernatx, Inc. |
Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
|
|
EP3833762A4
(en)
|
2018-08-09 |
2022-09-28 |
Verseau Therapeutics, Inc. |
Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
|
|
EP3842412B1
(en)
*
|
2018-08-21 |
2024-04-24 |
Kabushiki Kaisha Toshiba |
Biodegradable lipids for delivery of active compounds into tumor cells comprising two or more tertiary amino groups
|
|
US20220110966A1
(en)
|
2018-09-02 |
2022-04-14 |
Modernatx, Inc. |
Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency
|
|
MA53608A
(fr)
|
2018-09-13 |
2021-07-21 |
Modernatx Inc |
Polynucléotides codant pour les sous-unités e1-alpha, e1-beta et e2 du complexe alpha-cétoacide déshydrogénase à chaîne ramifiée pour le traitement de la leucinose
|
|
WO2020056147A2
(en)
|
2018-09-13 |
2020-03-19 |
Modernatx, Inc. |
Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease
|
|
CA3112398A1
(en)
|
2018-09-14 |
2020-03-19 |
Modernatx, Inc. |
Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
|
|
US12263248B2
(en)
|
2018-09-19 |
2025-04-01 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
EP4509118A3
(en)
|
2018-09-19 |
2025-05-14 |
ModernaTX, Inc. |
High-purity peg lipids and uses thereof
|
|
CA3113025A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Peg lipids and uses thereof
|
|
US12090235B2
(en)
|
2018-09-20 |
2024-09-17 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
EP3852911B1
(en)
|
2018-09-21 |
2025-01-22 |
Acuitas Therapeutics, Inc. |
Systems and methods for manufacturing lipid nanoparticles and liposomes
|
|
US20220152225A1
(en)
|
2018-09-27 |
2022-05-19 |
Modernatx, Inc. |
Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
|
|
JP7387745B2
(ja)
*
|
2018-10-01 |
2023-11-28 |
アルニラム・ファーマシューティカルズ・インコーポレーテッド |
活性物質の送達のための生分解性脂質
|
|
IL281948B2
(en)
*
|
2018-10-02 |
2025-05-01 |
Intellia Therapeutics Inc |
Ionizable amine lipids
|
|
US20220001026A1
(en)
|
2018-11-08 |
2022-01-06 |
Modernatx, Inc. |
Use of mrna encoding ox40l to treat cancer in human patients
|
|
EP3897702A2
(en)
|
2018-12-21 |
2021-10-27 |
CureVac AG |
Rna for malaria vaccines
|
|
US11453639B2
(en)
|
2019-01-11 |
2022-09-27 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
WO2020161342A1
(en)
|
2019-02-08 |
2020-08-13 |
Curevac Ag |
Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
|
|
WO2020208361A1
(en)
|
2019-04-12 |
2020-10-15 |
Mina Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
|
NZ781026A
(en)
*
|
2019-04-25 |
2025-07-25 |
Intellia Therapeutics Inc |
Ionizable amine lipids and lipid nanoparticles
|
|
EP3965806A1
(en)
|
2019-05-08 |
2022-03-16 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
|
|
EP3965797A1
(en)
|
2019-05-08 |
2022-03-16 |
AstraZeneca AB |
Compositions for skin and wounds and methods of use thereof
|
|
WO2020254535A1
(en)
|
2019-06-18 |
2020-12-24 |
Curevac Ag |
Rotavirus mrna vaccine
|
|
MA56539A
(fr)
|
2019-06-24 |
2022-04-27 |
Modernatx Inc |
Arn messager résistant à l'endonucléase et utilisations correspondantes
|
|
US20220387628A1
(en)
|
2019-06-24 |
2022-12-08 |
Modernatx, Inc. |
Messenger rna comprising functional rna elements and uses thereof
|
|
EP3999642A1
(en)
|
2019-07-19 |
2022-05-25 |
Flagship Pioneering Innovations VI, LLC |
Recombinase compositions and methods of use
|
|
JP7769325B2
(ja)
*
|
2019-07-23 |
2025-11-13 |
株式会社東芝 |
Ｃａｒ－ｔ細胞の製造方法、核酸導入キャリア及びキット
|
|
US20220296628A1
(en)
|
2019-08-14 |
2022-09-22 |
Curevac Ag |
Rna combinations and compositions with decreased immunostimulatory properties
|
|
HUE068356T2
(hu)
|
2019-08-14 |
2024-12-28 |
Acuitas Therapeutics Inc |
Javított lipid nanorészecskék nukleinsavak bejuttatására
|
|
CA3154618A1
(en)
|
2019-09-19 |
2021-03-25 |
Modernatx, Inc. |
Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
US11987791B2
(en)
|
2019-09-23 |
2024-05-21 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (HNF4α) gene expression
|
|
CN114391040A
(zh)
|
2019-09-23 |
2022-04-22 |
欧米茄治疗公司 |
用于调节载脂蛋白b(apob)基因表达的组合物和方法
|
|
IL294318A
(en)
|
2020-01-09 |
2022-08-01 |
Guide Therapeutics Llc |
Nanomaterials
|
|
KR20220144416A
(ko)
|
2020-02-04 |
2022-10-26 |
큐어백 아게 |
코로나바이러스 백신
|
|
MX2022010980A
(es)
|
2020-03-04 |
2022-12-02 |
Verve Therapeutics Inc |
Composiciones y metodos para el suministro de arn dirigido.
|
|
CN116096886A
(zh)
|
2020-03-11 |
2023-05-09 |
欧米茄治疗公司 |
用于调节叉头框p3(foxp3)基因表达的组合物和方法
|
|
MX2022011806A
(es)
|
2020-03-24 |
2023-01-11 |
Generation Bio Co |
Vectores de adn no virales y usos de estos para expresar agentes terapéuticos contra gaucher.
|
|
JP2023520764A
(ja)
|
2020-03-24 |
2023-05-19 |
ジェネレーション バイオ カンパニー |
第ｉｘ因子治療薬を発現するための非ウイルス性ｄｎａベクター及びその使用
|
|
CA3174588A1
(en)
|
2020-03-30 |
2021-10-07 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
US20230149560A1
(en)
|
2020-04-20 |
2023-05-18 |
Massachusetts Institute Of Technology |
Lipid compositions for delivery of sting agonist compounds and uses thereof
|
|
US12188060B2
(en)
|
2020-05-15 |
2025-01-07 |
Crispr Therapeutics Ag |
Messenger RNA encoding Cas9 for use in genome-editing systems
|
|
IL298362A
(en)
|
2020-05-20 |
2023-01-01 |
Flagship Pioneering Innovations Vi Llc |
Coronavirus antigen compositions and their uses
|
|
AU2021275213A1
(en)
|
2020-05-20 |
2023-02-02 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and uses thereof
|
|
AU2021281453A1
(en)
|
2020-05-29 |
2022-11-17 |
Flagship Pioneering Innovations Vi, Llc. |
Trem compositions and methods relating thereto
|
|
CA3180101A1
(en)
|
2020-05-29 |
2021-12-02 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods relating thereto
|
|
MX2022015132A
(es)
|
2020-05-29 |
2023-03-08 |
CureVac SE |
Vacunas combinadas a base de acidos nucleicos.
|
|
US20230235298A1
(en)
|
2020-06-01 |
2023-07-27 |
Modernatx, Inc. |
Phenylalanine hydroxylase variants and uses thereof
|
|
US20230272378A1
(en)
|
2020-06-12 |
2023-08-31 |
University Of Rochester |
ENCODING AND EXPRESSION OF ACE-tRNAs
|
|
WO2021257595A1
(en)
|
2020-06-15 |
2021-12-23 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus vector delivery for muscular dystrophies
|
|
WO2025056938A1
(en)
|
2023-09-11 |
2025-03-20 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
MX2023000614A
(es)
|
2020-07-16 |
2023-02-13 |
Acuitas Therapeutics Inc |
Lipidos cationicos para usarse en nanoparticulas lipidicas.
|
|
WO2022023284A1
(en)
|
2020-07-27 |
2022-02-03 |
Anjarium Biosciences Ag |
Compositions of dna molecules, methods of making therefor, and methods of use thereof
|
|
CA3170741A1
(en)
|
2020-07-31 |
2022-02-03 |
Curevac Ag |
Nucleic acid encoded antibody mixtures
|
|
CA3189854A1
(en)
|
2020-08-06 |
2022-02-10 |
Modernatx, Inc. |
Compositions for the delivery of payload molecules to airway epithelium
|
|
US20240066114A1
(en)
|
2020-08-31 |
2024-02-29 |
CureVac SE |
Multivalent nucleic acid based coronavirus vaccines
|
|
WO2022051629A1
(en)
|
2020-09-03 |
2022-03-10 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and uses thereof
|
|
AU2021377895A1
(en)
|
2020-11-13 |
2023-06-15 |
Modernatx, Inc. |
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
|
|
US11591544B2
(en)
|
2020-11-25 |
2023-02-28 |
Akagera Medicines, Inc. |
Ionizable cationic lipids
|
|
US20240050378A1
(en)
*
|
2020-12-02 |
2024-02-15 |
Merck Sharp & Dohme Llc |
Lipid nanoparticle compositions containing monoester cationic lipids
|
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
|
US20240299309A1
(en)
|
2020-12-22 |
2024-09-12 |
CureVac SE |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
|
WO2022137133A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Rna vaccine against sars-cov-2 variants
|
|
JP2024501288A
(ja)
|
2020-12-23 |
2024-01-11 |
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー |
修飾ｔｒｅｍの組成物及びその使用
|
|
CA3203628A1
(en)
|
2021-01-20 |
2022-07-28 |
Beam Therapeutics Inc. |
Nanomaterials comprising a biodegradable feature
|
|
WO2022162027A2
(en)
|
2021-01-27 |
2022-08-04 |
Curevac Ag |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
AU2022242828A1
(en)
|
2021-03-23 |
2023-10-12 |
Recode Therapeutics, Inc. |
Polynucleotide compositions, related formulations, and methods of use thereof
|
|
WO2022204380A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
|
|
WO2022204390A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
|
|
WO2022204369A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
|
|
US20240207374A1
(en)
|
2021-03-24 |
2024-06-27 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
|
|
JP2024512026A
(ja)
|
2021-03-24 |
2024-03-18 |
モデルナティエックス インコーポレイテッド |
オルニチントランスカルバミラーゼ欠損症の治療を目的とした脂質ナノ粒子及びオルニチントランスカルバミラーゼをコードするポリヌクレオチド
|
|
CA3212653A1
(en)
|
2021-03-26 |
2022-09-29 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions
|
|
EP4314292A1
(en)
|
2021-03-26 |
2024-02-07 |
MiNA Therapeutics Limited |
Tmem173 sarna compositions and methods of use
|
|
CA3214085A1
(en)
|
2021-03-31 |
2022-10-06 |
Darby Rye Schmidt |
Thanotransmission polypeptides and their use in treating cancer
|
|
WO2022207862A2
(en)
|
2021-03-31 |
2022-10-06 |
Curevac Ag |
Syringes containing pharmaceutical compositions comprising rna
|
|
WO2022212711A2
(en)
|
2021-04-01 |
2022-10-06 |
Modernatx, Inc. |
Methods for identification and ratio determination of rna species in multivalent rna compositions
|
|
WO2022215036A1
(en)
|
2021-04-08 |
2022-10-13 |
Vaxthera Sas |
Coronavirus vaccine comprising a mosaic protein
|
|
US20240148664A1
(en)
*
|
2021-04-09 |
2024-05-09 |
Sogo Pharmaceutical Co., Ltd. |
Lipid and composition
|
|
AU2022260111A1
(en)
|
2021-04-20 |
2023-11-30 |
Anjarium Biosciences Ag |
Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof
|
|
EP4329884A1
(en)
|
2021-04-27 |
2024-03-06 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
|
AU2022264509A1
(en)
|
2021-04-27 |
2023-12-14 |
Generation Bio Co. |
Non-viral dna vectors expressing therapeutic antibodies and uses thereof
|
|
WO2022233880A1
(en)
|
2021-05-03 |
2022-11-10 |
Curevac Ag |
Improved nucleic acid sequence for cell type specific expression
|
|
US20220389422A1
(en)
*
|
2021-05-06 |
2022-12-08 |
Arcturus Therapeutics, Inc. |
Ionizable cationic lipids for rna delivery
|
|
EP4337177A1
(en)
|
2021-05-11 |
2024-03-20 |
Modernatx, Inc. |
Non-viral delivery of dna for prolonged polypeptide expression in vivo
|
|
WO2022246020A1
(en)
|
2021-05-19 |
2022-11-24 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
|
|
EP4355882A2
(en)
|
2021-06-15 |
2024-04-24 |
Modernatx, Inc. |
Engineered polynucleotides for cell-type or microenvironment-specific expression
|
|
US20240376445A1
(en)
|
2021-06-22 |
2024-11-14 |
Modernatx, Inc. |
Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
|
|
WO2023283359A2
(en)
|
2021-07-07 |
2023-01-12 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
|
US20240316165A1
(en)
|
2021-07-12 |
2024-09-26 |
Modernatx, Inc. |
Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia
|
|
AU2022316139A1
(en)
|
2021-07-23 |
2024-01-18 |
Alnylam Pharmaceuticals, Inc. |
Beta-catenin (ctnnb1) irna compositions and methods of use thereof
|
|
EP4377457A1
(en)
|
2021-07-26 |
2024-06-05 |
Flagship Pioneering Innovations VI, LLC |
Trem compositions and uses thereof
|
|
US20250090684A1
(en)
|
2021-07-27 |
2025-03-20 |
Modernatx, Inc. |
Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease type 1a (gsd1a)
|
|
WO2023015261A1
(en)
|
2021-08-04 |
2023-02-09 |
Modernatx, Inc. |
Mrnas encoding chimeric metabolic reprogramming polypeptides and uses thereof
|
|
WO2023023055A1
(en)
|
2021-08-16 |
2023-02-23 |
Renagade Therapeutics Management Inc. |
Compositions and methods for optimizing tropism of delivery systems for rna
|
|
AU2022336209B2
(en)
|
2021-09-03 |
2025-10-16 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids
|
|
AU2022336664A1
(en)
|
2021-09-03 |
2024-01-18 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
|
|
CA3229889A1
(en)
|
2021-09-03 |
2023-03-09 |
Glaxosmithkline Biologicals Sa |
Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids
|
|
EP4402123A1
(en)
|
2021-09-14 |
2024-07-24 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and methods of use thereof
|
|
EP4402121A1
(en)
|
2021-09-14 |
2024-07-24 |
Renagade Therapeutics Management Inc. |
Acyclic lipids and methods of use thereof
|
|
EP4271818B1
(en)
|
2021-09-17 |
2024-07-31 |
Flagship Pioneering Innovations VI, LLC |
Compositions and methods for producing circular polyribonucleotides
|
|
US20250281596A1
(en)
*
|
2021-09-28 |
2025-09-11 |
Seqirus Inc. |
Ionizable cationic compound
|
|
US20250017867A1
(en)
|
2021-10-01 |
2025-01-16 |
Modernatx, Inc. |
Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
|
|
TW202322826A
(zh)
|
2021-10-18 |
2023-06-16 |
美商旗艦先鋒創新有限責任公司 |
用於純化多核糖核苷酸之組成物及方法
|
|
US20250027108A1
(en)
|
2021-10-29 |
2025-01-23 |
CureVac SE |
Improved circular rna for expressing therapeutic proteins
|
|
US20250041393A1
(en)
|
2021-11-01 |
2025-02-06 |
Modernatx, Inc. |
Polynucleotides encoding integrin beta-6 and methods of use thereof
|
|
EP4426828A1
(en)
|
2021-11-01 |
2024-09-11 |
Tome Biosciences, Inc. |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|
|
WO2023081756A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
|
WO2023081526A1
(en)
|
2021-11-08 |
2023-05-11 |
Orna Therapeutics, Inc. |
Lipid nanoparticle compositions for delivering circular polynucleotides
|
|
US20250049727A1
(en)
|
2021-11-12 |
2025-02-13 |
Modernatx, Inc. |
Compositions for the delivery of payload molecules to airway epithelium
|
|
JP2024542188A
(ja)
|
2021-11-16 |
2024-11-13 |
セイル バイオメディシンズ インコーポレイテッド |
新規イオン化可能な脂質および脂質ナノ粒子ならびにそれらを使用する方法
|
|
AU2022390215A1
(en)
|
2021-11-18 |
2024-06-20 |
Astrazeneca Ab |
Novel lipids for delivery of nucleic acid segments
|
|
EP4436549A1
(en)
|
2021-11-22 |
2024-10-02 |
Sail Biomedicines, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
US20250352638A1
(en)
|
2021-11-24 |
2025-11-20 |
Flagship Pioneering Innovations Vi, Llc |
Coronavirus immunogen compositions and their uses
|
|
MX2024006440A
(es)
|
2021-11-24 |
2024-08-19 |
Flagship Pioneering Innovations Vi Llc |
Composiciones inmunogenicas y sus usos.
|
|
CA3238370A1
(en)
|
2021-11-24 |
2023-06-01 |
Flagship Pioneering Innovations Vi, Llc |
Varicella-zoster virus immunogen compositions and their uses
|
|
WO2023099884A1
(en)
|
2021-12-01 |
2023-06-08 |
Mina Therapeutics Limited |
Pax6 sarna compositions and methods of use
|
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
|
IL313486A
(en)
|
2021-12-16 |
2024-08-01 |
Acuitas Therapeutics Inc |
Lipids for use in lipid nanoparticle formulations
|
|
WO2023115013A1
(en)
|
2021-12-17 |
2023-06-22 |
Flagship Pioneering Innovations Vi, Llc |
Methods for enrichment of circular rna under denaturing conditions
|
|
CA3241488A1
(en)
*
|
2021-12-20 |
2023-06-29 |
Beam Therapeutics Inc. |
Ionizable amine lipids and lipid nanoparticles
|
|
JP2025500360A
(ja)
|
2021-12-22 |
2025-01-09 |
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー |
ポリリボヌクレオチドを精製するための組成物及び方法
|
|
CA3244180A1
(en)
|
2021-12-22 |
2023-06-29 |
Tome Biosciences Inc |
CO-ADMINISTRATION OF A GENE EDITOR CONSTRUCTION AND A PATTERN DONOR
|
|
EP4452928A1
(en)
|
2021-12-23 |
2024-10-30 |
Renagade Therapeutics Management Inc. |
Constrained lipids and methods of use thereof
|
|
IL313714A
(en)
|
2021-12-23 |
2024-08-01 |
Flagship Pioneering Innovations Vi Llc |
Cyclic polyribonucleotides encoding antifusogenic polypeptides
|
|
WO2023135273A2
(en)
|
2022-01-14 |
2023-07-20 |
Anjarium Biosciences Ag |
Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
IL314324A
(en)
|
2022-01-27 |
2024-09-01 |
BioNTech SE |
Pharmaceutical preparations for administration of herpes simplex virus antigens and related methods
|
|
US20250099614A1
(en)
|
2022-01-28 |
2025-03-27 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
|
AU2023215397A1
(en)
|
2022-02-07 |
2024-08-22 |
University Of Rochester |
Optimized sequences for enhanced trna expression or/and nonsense mutation suppression.
|
|
EP4475882A1
(en)
|
2022-02-09 |
2024-12-18 |
ModernaTX, Inc. |
Mucosal administration methods and formulations
|
|
JP2025507571A
(ja)
|
2022-02-18 |
2025-03-21 |
モデルナティエックス インコーポレイテッド |
チェックポイントがんワクチンをコードするｍＲＮＡ及びその使用
|
|
US20250327041A1
(en)
|
2022-02-24 |
2025-10-23 |
Io Biotech Aps |
Nucleotide delivery of cancer therapy
|
|
WO2023170435A1
(en)
|
2022-03-07 |
2023-09-14 |
Mina Therapeutics Limited |
Il10 sarna compositions and methods of use
|
|
KR20240161965A
(ko)
|
2022-03-14 |
2024-11-13 |
제너레이션 바이오 컴퍼니 |
이종 프라임 부스트 백신 조성물 및 사용 방법
|
|
WO2023177904A1
(en)
|
2022-03-18 |
2023-09-21 |
Modernatx, Inc. |
Sterile filtration of lipid nanoparticles and filtration analysis thereof for biological applications
|
|
WO2023183909A2
(en)
|
2022-03-25 |
2023-09-28 |
Modernatx, Inc. |
Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
|
|
CN119072464A
(zh)
|
2022-03-25 |
2024-12-03 |
赛欧生物医药股份有限公司 |
新型可电离脂质和脂质纳米颗粒以及其使用方法
|
|
CN116354836A
(zh)
*
|
2022-03-25 |
2023-06-30 |
深圳市新合生物医疗科技有限公司 |
阳离子脂质化合物及其制备方法和应用、以及mRNA递送系统
|
|
WO2023196399A1
(en)
|
2022-04-06 |
2023-10-12 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria
|
|
CA3255619A1
(en)
|
2022-04-07 |
2023-10-12 |
Renagade Therapeutics Man Inc |
CYCLIC LIPIDS AND LIPID NANOPARTICLES (LPNs) FOR THE SUPPLY OF NUCLEIC ACIDS OR PEPTIDES INTENDED FOR USE IN VACCINATION AGAINST INFECTIOUS AGENTS
|
|
JP2025511756A
(ja)
|
2022-04-08 |
2025-04-16 |
フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー |
ワクチン及び関連する方法
|
|
US20250250614A1
(en)
|
2022-04-11 |
2025-08-07 |
c/o ModernaTX, Inc. |
Detection of mrna purity in a mixture
|
|
WO2023205744A1
(en)
|
2022-04-20 |
2023-10-26 |
Tome Biosciences, Inc. |
Programmable gene insertion compositions
|
|
CN115850104B
(zh)
*
|
2022-04-29 |
2023-07-18 |
北京剂泰医药科技有限公司 |
可电离脂质化合物
|
|
EP4332087A1
(en)
|
2022-04-29 |
2024-03-06 |
Beijing Jitai Pharmaceutical Technology Co., Ltd. |
Lipid nanoparticles
|
|
CN116969851A
(zh)
|
2022-04-29 |
2023-10-31 |
北京剂泰医药科技有限公司 |
可电离脂质化合物
|
|
CN117243922A
(zh)
*
|
2022-04-29 |
2023-12-19 |
北京剂泰医药科技有限公司 |
脂质纳米颗粒
|
|
WO2023215831A1
(en)
|
2022-05-04 |
2023-11-09 |
Tome Biosciences, Inc. |
Guide rna compositions for programmable gene insertion
|
|
WO2023215498A2
(en)
|
2022-05-05 |
2023-11-09 |
Modernatx, Inc. |
Compositions and methods for cd28 antagonism
|
|
WO2023220083A1
(en)
|
2022-05-09 |
2023-11-16 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods of use for treating proliferative disorders
|
|
EP4522753A2
(en)
|
2022-05-13 |
2025-03-19 |
Flagship Pioneering Innovations VII, LLC |
Double stranded dna compositions and related methods
|
|
CA3252451A1
(en)
|
2022-05-13 |
2023-11-16 |
BioNTech SE |
HIV-TARGETING RNA COMPOSITIONS
|
|
WO2023225524A1
(en)
|
2022-05-17 |
2023-11-23 |
Modernatx, Inc. |
Preparation of highly concentrated mrna
|
|
WO2023225670A2
(en)
|
2022-05-20 |
2023-11-23 |
Tome Biosciences, Inc. |
Ex vivo programmable gene insertion
|
|
CA3253434A1
(en)
|
2022-05-25 |
2023-11-30 |
BioNTech SE |
RNA COMPOSITIONS FOR THE ADMINISTRATION OF MONKEY POULTRY ANTIGENS AND ASSOCIATED METHODS
|
|
AU2023274371A1
(en)
|
2022-05-25 |
2024-10-31 |
CureVac SE |
Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
|
|
AU2023275780A1
(en)
|
2022-05-25 |
2024-12-05 |
Akagera Medicines, Inc. |
Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
|
|
CN119562807A
(zh)
|
2022-05-30 |
2025-03-04 |
生物技术公司 |
用于递送核酸的复合物
|
|
EP4536197A1
(en)
|
2022-06-07 |
2025-04-16 |
Generation Bio Co. |
Lipid nanoparticle compositions and uses thereof
|
|
CN119604304A
(zh)
|
2022-06-18 |
2025-03-11 |
葛兰素史克生物有限公司 |
包含非翻译区或编码来自严重急性呼吸道冠状病毒2奥密克戎毒株刺突蛋白的区段的重组rna分子
|
|
WO2023248125A1
(en)
|
2022-06-20 |
2023-12-28 |
Crispr Therapeutics Ag |
Cd117-targeting nanoparticles for use in drug delivery
|
|
EP4544043A1
(en)
|
2022-06-22 |
2025-04-30 |
Flagship Pioneering Innovations VI, LLC |
Compositions of modified trems and uses thereof
|
|
WO2023250119A1
(en)
|
2022-06-24 |
2023-12-28 |
Modernatx, Inc. |
Methods of producing rna
|
|
CN114874106B
(zh)
*
|
2022-07-11 |
2023-04-14 |
中山大学附属第七医院(深圳) |
一种氨基脂质及其制备方法和应用
|
|
MA71557A
(fr)
|
2022-07-18 |
2025-05-30 |
Renagade Therapeutics Management Inc. |
Composants d'édition génique, systèmes et procédés d'utilisation
|
|
WO2024019936A1
(en)
|
2022-07-20 |
2024-01-25 |
Beam Therapeutics Inc. |
Nanomaterials comprising triols
|
|
TW202412818A
(zh)
|
2022-07-26 |
2024-04-01 |
美商現代公司 |
用於暫時控制表現之經工程化多核苷酸
|
|
WO2024026308A2
(en)
|
2022-07-29 |
2024-02-01 |
Massachusetts Institute Of Technology |
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE SIGNAL REGULATORY PROTEIN ALPHA (SIRPα) GENE
|
|
CN120129693A
(zh)
|
2022-08-01 |
2025-06-10 |
旗舰创业创新第七有限责任公司 |
免疫调节蛋白及相关方法
|
|
WO2024031051A1
(en)
*
|
2022-08-05 |
2024-02-08 |
Life Technologies Corporation |
Lipids for nucleic acid delivery
|
|
EP4569112A1
(en)
|
2022-08-12 |
2025-06-18 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
|
EP4572772A1
(en)
|
2022-08-17 |
2025-06-25 |
Capstan Therapeutics, Inc. |
Conditioning for in vivo immune cell engineering
|
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
|
EP4577519A1
(en)
|
2022-08-23 |
2025-07-02 |
ModernaTX, Inc. |
Methods for purification of ionizable lipids
|
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
EP4581012A2
(en)
|
2022-08-31 |
2025-07-09 |
Sail Biomedicines, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
EP4342460A1
(en)
|
2022-09-21 |
2024-03-27 |
NovoArc GmbH |
Lipid nanoparticle with nucleic acid cargo
|
|
WO2024064931A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of liver stage antigens and related methods
|
|
AU2023347320A1
(en)
|
2022-09-23 |
2025-04-10 |
Nchroma Bio, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
WO2024063788A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
CN120152736A
(zh)
|
2022-09-23 |
2025-06-13 |
生物技术欧洲股份公司 |
用于递送疟原虫csp抗原的组合物及相关方法
|
|
WO2024063789A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
CN117800859A
(zh)
*
|
2022-09-26 |
2024-04-02 |
苏州科锐迈德生物医药科技有限公司 |
具有戊二酸骨架的脂质化合物及基于其的脂质载体、核酸脂质纳米粒组合物和药物制剂
|
|
WO2024068545A1
(en)
|
2022-09-26 |
2024-04-04 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
WO2024074211A1
(en)
|
2022-10-06 |
2024-04-11 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
JP2025534447A
(ja)
|
2022-10-06 |
2025-10-15 |
バイオエヌテック エスエー |
クローディン１８．２を標的とするｒｎａ組成物
|
|
WO2024089638A1
(en)
|
2022-10-28 |
2024-05-02 |
Glaxosmithkline Biologicals Sa |
Nucleic acid based vaccine
|
|
WO2024097639A1
(en)
|
2022-10-31 |
2024-05-10 |
Modernatx, Inc. |
Hsa-binding antibodies and binding proteins and uses thereof
|
|
AU2023372397A1
(en)
|
2022-10-31 |
2025-05-08 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for purifying polyribonucleotides
|
|
EP4615465A1
(en)
|
2022-11-08 |
2025-09-17 |
Flagship Pioneering Innovations VI, LLC |
Compositions and methods for producing circular polyribonucleotides
|
|
TW202425959A
(zh)
|
2022-11-08 |
2024-07-01 |
美商歐納醫療公司 |
遞送多核苷酸的脂質及奈米顆粒組合物
|
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
TW202428289A
(zh)
|
2022-11-08 |
2024-07-16 |
美商歐納醫療公司 |
環狀rna組合物
|
|
AU2023406303A1
(en)
|
2022-12-01 |
2025-05-29 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids, ionizable lipids, sterols, lipid anchored polymers and helper lipids, their uses
|
|
EP4626401A1
(en)
|
2022-12-01 |
2025-10-08 |
Generation Bio Co. |
Stealth lipid nanoparticle compositions for cell targeting
|
|
EP4626402A1
(en)
|
2022-12-01 |
2025-10-08 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
|
|
AU2023406321A1
(en)
|
2022-12-01 |
2025-05-29 |
Generation Bio Co. |
Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
|
|
WO2024118866A1
(en)
|
2022-12-01 |
2024-06-06 |
Modernatx, Inc. |
Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
|
|
CN120693181A
(zh)
|
2022-12-08 |
2025-09-23 |
瑞科德治疗公司 |
脂质纳米颗粒组合物及其用途
|
|
EP4634388A1
(en)
|
2022-12-14 |
2025-10-22 |
Providence Therapeutics Holdings Inc. |
Compositions and methods for infectious diseases
|
|
EP4385523A1
(en)
|
2022-12-14 |
2024-06-19 |
Beijing Jitai Pharmaceutical Technology Co., Ltd. |
Lipid-based topical injection formulations
|
|
TW202430215A
(zh)
|
2022-12-14 |
2024-08-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
用於將治療劑遞送至骨之組成物和方法
|
|
WO2024130158A1
(en)
|
2022-12-16 |
2024-06-20 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
|
|
WO2024133160A1
(en)
|
2022-12-19 |
2024-06-27 |
Glaxosmithkline Biologicals Sa |
Hepatitis b compositions
|
|
WO2024131832A1
(zh)
*
|
2022-12-20 |
2024-06-27 |
北京剂泰医药科技有限公司 |
可电离脂质化合物
|
|
WO2024138194A1
(en)
|
2022-12-22 |
2024-06-27 |
Tome Biosciences, Inc. |
Platforms, compositions, and methods for in vivo programmable gene insertion
|
|
WO2024130421A1
(en)
|
2022-12-22 |
2024-06-27 |
Nanovation Therapeutics Inc. |
Sulfur-containing ionizable lipids for the delivery of nucleic acids and other therapeutic agents
|
|
WO2024134199A1
(en)
|
2022-12-22 |
2024-06-27 |
Mina Therapeutics Limited |
Chemically modified sarna compositions and methods of use
|
|
CN121127490A
(zh)
|
2022-12-28 |
2025-12-12 |
生物技术欧洲股份公司 |
靶向hiv的rna组合物
|
|
WO2024151673A2
(en)
|
2023-01-09 |
2024-07-18 |
President And Fellows Of Harvard College |
Recombinant nucleic acid molecules and their use in wound healing
|
|
US20240252520A1
(en)
|
2023-01-09 |
2024-08-01 |
Beth Israel Deaconess Medical Center, Inc. |
Therapeutic agents and their use for treating chronic wounds
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
TW202438673A
(zh)
|
2023-01-09 |
2024-10-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
疫苗及相關方法
|
|
WO2024151877A2
(en)
|
2023-01-11 |
2024-07-18 |
Engage Biologics Inc. |
Non-viral expression systems and methods of use thereof
|
|
WO2024151811A1
(en)
|
2023-01-11 |
2024-07-18 |
Modernatx, Inc. |
Personalized cancer vaccines
|
|
WO2024156291A1
(en)
*
|
2023-01-29 |
2024-08-02 |
Geneditbio Limited |
Cationic lipids and lipid nanoparticles
|
|
EP4658239A1
(en)
|
2023-02-03 |
2025-12-10 |
GlaxoSmithKline Biologicals S.A. |
Rna formulation
|
|
TW202438515A
(zh)
|
2023-02-06 |
2024-10-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
免疫調節組合物及相關方法
|
|
KR20250144467A
(ko)
|
2023-02-09 |
2025-10-10 |
알닐람 파마슈티칼스 인코포레이티드 |
Reversir 분자 및 이의 사용 방법
|
|
AU2024218499A1
(en)
*
|
2023-02-09 |
2025-08-14 |
Seqirus Inc. |
Ionizable cationic compound
|
|
US20240293318A1
(en)
|
2023-02-13 |
2024-09-05 |
Flagship Pioneering Innovations Vii, Llc |
Cleavable linker-containing ionizable lipids and lipid carriers for therapeutic compositions
|
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
|
IL322201A
(en)
|
2023-02-17 |
2025-09-01 |
Flagship Pioneering Innovations Vii Llc |
DNA structures containing modified uracil
|
|
US20240293582A1
(en)
|
2023-02-17 |
2024-09-05 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions comprising modified cytosine
|
|
WO2024182301A2
(en)
|
2023-02-27 |
2024-09-06 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding galactose-1-phosphate uridylyltransferase (galt) for the treatment of galactosemia
|
|
AU2024233180A1
(en)
|
2023-03-08 |
2025-09-25 |
CureVac SE |
Novel lipid nanoparticle formulations for delivery of nucleic acids
|
|
WO2024192277A2
(en)
|
2023-03-15 |
2024-09-19 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
KR20250162610A
(ko)
|
2023-03-15 |
2025-11-18 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
폴리리보뉴클레오티드를 포함하는 조성물 및 이의 용도
|
|
AU2024236558A1
(en)
|
2023-03-15 |
2025-10-09 |
Renagade Therapeutics Management Inc. |
Delivery of gene editing systems and methods of use thereof
|
|
WO2024192422A1
(en)
|
2023-03-15 |
2024-09-19 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and uses thereof
|
|
WO2024197033A1
(en)
|
2023-03-21 |
2024-09-26 |
Modernatx, Inc. |
Polynucleotides encoding relaxin for the treatment of heart failure
|
|
WO2024206126A1
(en)
|
2023-03-27 |
2024-10-03 |
Modernatx, Inc. |
Cd16-binding antibodies and uses thereof
|
|
WO2024206329A1
(en)
|
2023-03-27 |
2024-10-03 |
Modernatx, Inc. |
Nucleic acid molecules encoding bi-specific secreted engagers and uses thereof
|
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
WO2024206835A1
(en)
|
2023-03-30 |
2024-10-03 |
Modernatx, Inc. |
Circular mrna and production thereof
|
|
AU2024252590A1
(en)
|
2023-04-12 |
2025-10-23 |
Flagship Pioneering Innovations Vi, Llc |
Trems for use in correction of missense mutations
|
|
AU2024255972A1
(en)
|
2023-04-12 |
2025-10-23 |
Flagship Pioneering Innovations Vi, Llc |
Modified trems, compositions, and related methods thereof
|
|
WO2024220746A2
(en)
|
2023-04-21 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Rnai agents targeting fatty acid synthase and related methods
|
|
WO2024223728A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2024223724A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2024229321A1
(en)
|
2023-05-03 |
2024-11-07 |
Modernatx, Inc. |
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
|
|
WO2024228044A1
(en)
|
2023-05-03 |
2024-11-07 |
BioNTech SE |
Optimized csp variants and related methods
|
|
CN121038807A
(zh)
|
2023-05-03 |
2025-11-28 |
生物技术欧洲股份公司 |
优化的csp变体及相关方法
|
|
AU2024266138A1
(en)
|
2023-05-03 |
2025-11-13 |
Manifold Biotechnologies, Inc. |
Methods and compositions for high-throughput protein delivery, screening, and detection
|
|
WO2024233308A2
(en)
|
2023-05-05 |
2024-11-14 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
WO2024230934A1
(en)
|
2023-05-11 |
2024-11-14 |
CureVac SE |
Therapeutic nucleic acid for the treatment of ophthalmic diseases
|
|
WO2024234006A1
(en)
|
2023-05-11 |
2024-11-14 |
Tome Biosciences, Inc. |
Systems, compositions, and methods for targeting liver sinusodial endothelial cells (lsecs)
|
|
AU2024270764A1
(en)
|
2023-05-15 |
2025-12-04 |
Nchroma Bio, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
WO2024238700A1
(en)
|
2023-05-15 |
2024-11-21 |
Chroma Medicine, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
WO2024243438A2
(en)
|
2023-05-23 |
2024-11-28 |
Omega Therapeutics, Inc. |
Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
|
|
US12311033B2
(en)
|
2023-05-31 |
2025-05-27 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
WO2024258829A1
(en)
|
2023-06-12 |
2024-12-19 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2025006799A1
(en)
|
2023-06-27 |
2025-01-02 |
Capstan Therapeutics, Inc. |
Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
|
|
WO2025006684A1
(en)
|
2023-06-28 |
2025-01-02 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
WO2025007148A1
(en)
|
2023-06-30 |
2025-01-02 |
Orna Therapeutics, Inc. |
Polymer lipid nanoparticle compositions for delivering circular polynucleotides
|
|
WO2025011529A2
(en)
|
2023-07-07 |
2025-01-16 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna vaccines for seasonal flu and methods of uses
|
|
WO2025024335A2
(en)
|
2023-07-21 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
WO2025024324A1
(en)
|
2023-07-21 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
WO2025024337A1
(en)
|
2023-07-24 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
WO2025024486A2
(en)
|
2023-07-25 |
2025-01-30 |
Flagship Pioneering Innovations Vii, Llc |
Cas endonucleases and related methods
|
|
WO2025026545A1
(en)
|
2023-08-01 |
2025-02-06 |
BioNTech SE |
Ionizable thioplipids and uses thereof
|
|
WO2025027089A1
(en)
|
2023-08-01 |
2025-02-06 |
BioNTech SE |
Ionizable thiolipids and uses thereof
|
|
WO2025027576A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2025027579A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2025030154A1
(en)
|
2023-08-03 |
2025-02-06 |
The Trustees Of The University Of Pennsylvania |
Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods
|
|
WO2025030097A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
|
|
WO2025034422A1
(en)
|
2023-08-04 |
2025-02-13 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating ctnnb1-associated disorders
|
|
WO2025042786A1
(en)
|
2023-08-18 |
2025-02-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising circular polyribonucleotides and uses thereof
|
|
CN117088820B
(zh)
*
|
2023-08-18 |
2025-11-28 |
苏州信使生物科技有限公司 |
一种新型阳离子lnp递送系统及制备方法
|
|
WO2025042806A2
(en)
|
2023-08-21 |
2025-02-27 |
Modernatx, Inc. |
C-met binding antibodies, nucleic acids encoding same, and methods of use
|
|
WO2025045142A1
(en)
|
2023-08-29 |
2025-03-06 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna encoding vegf polypeptides, formulations, and methods of uses
|
|
WO2025049690A1
(en)
|
2023-08-29 |
2025-03-06 |
Orna Therapeutics, Inc. |
Circular polyethylene glycol lipids
|
|
WO2025049959A2
(en)
|
2023-09-01 |
2025-03-06 |
Renagade Therapeutics Management Inc. |
Gene editing systems, compositions, and methods for treatment of vexas syndrome
|
|
WO2025046121A1
(en)
|
2023-09-01 |
2025-03-06 |
Novoarc Gmbh |
Lipid nanoparticle with nucleic acid cargo and ionizable lipid
|
|
WO2025050069A1
(en)
|
2023-09-01 |
2025-03-06 |
Tome Biosciences, Inc. |
Programmable gene insertion using engineered integration enzymes
|
|
WO2025054236A2
(en)
|
2023-09-06 |
2025-03-13 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
EP4520345A1
(en)
|
2023-09-06 |
2025-03-12 |
Myneo Nv |
Product
|
|
WO2025054556A1
(en)
|
2023-09-07 |
2025-03-13 |
BioNTech SE |
Rna compositions for delivery of mpox antigens and related methods
|
|
WO2025052180A2
(en)
|
2023-09-07 |
2025-03-13 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2025057088A1
(en)
|
2023-09-11 |
2025-03-20 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
WO2025059290A1
(en)
|
2023-09-14 |
2025-03-20 |
Modernatx, Inc. |
Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
|
|
WO2025064475A2
(en)
|
2023-09-18 |
2025-03-27 |
Flagship Pioneering Innovations Vii, Llc |
Ionizable lipidoid compositions and therapeutic uses thereof
|
|
WO2025064850A1
(en)
|
2023-09-22 |
2025-03-27 |
BioNTech SE |
Rna constructs with n-terminal degrons to enhance an immune response
|
|
WO2025072331A1
(en)
|
2023-09-26 |
2025-04-03 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025072482A1
(en)
|
2023-09-27 |
2025-04-03 |
Modernatx, Inc. |
Immunoglobulin a protease polypeptides, polynucleotides, and uses thereof
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025077836A1
(en)
*
|
2023-10-13 |
2025-04-17 |
Beigene Switzerland Gmbh |
Ionizable lipids and lipid nanoparticles for rna delivery
|
|
WO2025096807A2
(en)
|
2023-10-31 |
2025-05-08 |
Flagship Pioneering Innovations Vii, Llc |
Novel therapeutic dna forms
|
|
WO2025101501A1
(en)
|
2023-11-07 |
2025-05-15 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
WO2025101685A1
(en)
|
2023-11-09 |
2025-05-15 |
University Of Rochester |
Suppression of nonsense mutations using anticodon engineered (ace)-trnas
|
|
TW202535835A
(zh)
|
2023-11-14 |
2025-09-16 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
可電離類脂質組成物及其治療用途
|
|
WO2025106754A1
(en)
|
2023-11-15 |
2025-05-22 |
BioNTech SE |
Coronavirus vaccine
|
|
WO2025111297A1
(en)
|
2023-11-21 |
2025-05-30 |
Modernatx, Inc. |
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
|
|
TW202523695A
(zh)
|
2023-11-22 |
2025-06-16 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
用於治療非酒精性脂肪性肝病之方法及組成物
|
|
US12364773B2
(en)
|
2023-12-01 |
2025-07-22 |
Recode Therapeutics, Inc. |
Lipid nanoparticle compositions and uses thereof
|
|
WO2025117877A2
(en)
|
2023-12-01 |
2025-06-05 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
CN119143714B
(zh)
*
|
2023-12-11 |
2025-06-10 |
仁景(苏州)生物科技有限公司 |
用于递送的脂质化合物和脂质纳米颗粒
|
|
WO2025128871A2
(en)
|
2023-12-13 |
2025-06-19 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025124711A1
(en)
|
2023-12-13 |
2025-06-19 |
BioNTech SE |
Glycolipid compositions
|
|
WO2025129201A1
(en)
|
2023-12-15 |
2025-06-19 |
Capstan Therapeutics, Inc. |
Humanized anti-cd8 antibodies and uses thereof
|
|
WO2025133105A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Compositions and methods
|
|
WO2025132839A1
(en)
|
2023-12-21 |
2025-06-26 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2025134066A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Ionizable lipids
|
|
TW202525287A
(zh)
|
2023-12-21 |
2025-07-01 |
德商拜恩技術運輸科技有限責任公司 |
可離子化脂質
|
|
WO2025137646A1
(en)
|
2023-12-22 |
2025-06-26 |
Recode Therapeutics, Inc. |
Gene editing methods and compositions for treating cystic fibrosis
|
|
WO2025144938A1
(en)
|
2023-12-26 |
2025-07-03 |
Emmune, Inc. |
Systems for nucleic acid transfer
|
|
WO2025149492A1
(en)
|
2024-01-08 |
2025-07-17 |
BioNTech SE |
Rna encoding an immune inhibitory il-1 family member
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
US20250375499A1
(en)
|
2024-01-26 |
2025-12-11 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025166238A1
(en)
|
2024-01-31 |
2025-08-07 |
Orna Therapeutics, Inc. |
Fast-shedding polyethylene glycol lipids
|
|
WO2025171182A1
(en)
|
2024-02-08 |
2025-08-14 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025184508A1
(en)
|
2024-03-01 |
2025-09-04 |
Acuitas Therapeutics, Inc. |
Materials and methods for encapsulating therapeutics in lipid nanoparticles
|
|
WO2025194019A1
(en)
|
2024-03-14 |
2025-09-18 |
Flagship Pioneering Innovations Vii, Llc |
Methods for treating liver fibrosis and non-alcoholic fatty liver disease
|
|
WO2025202937A1
(en)
|
2024-03-26 |
2025-10-02 |
BioNTech SE |
Cancer vaccines
|
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|
|
WO2025213131A1
(en)
|
2024-04-05 |
2025-10-09 |
BioNTech SE |
Rna compositions for delivery of orthopox antigens and related methods
|
|
WO2025217275A2
(en)
|
2024-04-10 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Immune cell targeted compositions and related methods
|
|
WO2025224107A1
(en)
|
2024-04-22 |
2025-10-30 |
Basecamp Research Ltd |
Method and compositions for detecting off-target editing
|
|
WO2025224182A2
(en)
|
2024-04-23 |
2025-10-30 |
Basecamp Research Ltd |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|
|
WO2025229572A1
(en)
|
2024-05-01 |
2025-11-06 |
Glaxosmithkline Biologicals Sa |
Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines
|
|
US20250353881A1
(en)
|
2024-05-16 |
2025-11-20 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025245188A2
(en)
|
2024-05-21 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Methods of treating liver steatosis and non-alcoholic fatty liver disease
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|